Scancell Holdings Plc, (PLUS:SCLP), the developer of therapeutic cancer vaccines, announces a research collaboration with immatics biotechnologies GmbH ("immatics") to explore the development of novel ImmunoBody® vaccines for colorectal cancer. Immatics discovers and develops tumor-associated peptides (TUMAPs) for the immunotherapy of cancer. TUMAPs with the highest specificity for particular cancers are identified directly from primary human tumour tissue samples...
More...
More...